ArticleUpdates in surgery2025
Clinical application of the KangDuo-Surgical Robot-01 in distal gastrectomy for gastric cancer.
Article in Updates in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to explore the safety, feasibility, and efficacy of using KangDuo-Surgical Robot-01 (KD-SR-01) for distal gastrectomy in patients with gastric cancer. We prospectively enrolled patients undergoing KD-SR-01 assisted distal gastrectomy at our center from September 2023 to December 2023. Data on baseline characteristics, perioperative details, and short-term follow-up were collected prospectively. Descriptive statistical analysis was performed. This study included 15 patients with a median age of 60 years (range: 44-74) and a median body mass index of 24.7 [interquartile range (IQR): 19.8-27.0]. None of the patients required conversion to laparotomy or open surgery during lymphadenectomy. Ten patients underwent D2+ lymphadenectomy, four had D2, and one had D1+. Eleven patients had robotic-assisted BII anastomosis, one had robotic-assisted BI anastomosis, and three had laparoscopic BII anastomosis. All patients had negative surgical margins. The median operative time was 210.0 min (IQR: 200.0-225.0), with a median anastomosis time of 32.0 min (IQR: 21.5-54.5) for robotic-assisted BII anastomosis and 20 min for BI anastomosis. The median estimated blood loss was 30 ml (range: 30-50), and the median postoperative hospital stay was 7.0 days (IQR: 7.0-8.0). Four patients (26.7%) experienced Clavien-Dindo grade II postoperative complications, including two cases of hypoalbuminemia, one case of pneumonia, and one case of moderate anemia, with no device-related complications. Short-term follow-up indicated normal postoperative recovery with no radiographic evidence of recurrence. The KD-SR-01 is safe, feasible, and effective for distal gastrectomy and robotic-assisted gastrointestinal reconstruction.
Indexed as
Identifiers
39831930What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.